NCT06163898View on ClinicalTrials.gov

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Alnuctamab

Specified dose on specified days

DRUG

Mezigdomide

Specified dose on specified days

DRUG

Dexamethasone

Specified dose on specified days

Trial Locations (6)

10065

Local Institution - 0018, New York

35294

Local Institution - 0033, Birmingham

4910021

Local Institution - 0021, Petah Tikva

5262100

Local Institution - 0030, Ramat Gan

9112001

Local Institution - 0020, Jerusalem

06511

Local Institution - 0035, New Haven

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY